Last updated on January 2019

Study of RC48-ADC in Patients With HER2-Positive Advanced Malignant Solid Tumors


Brief description of study

A tolerance, safety and pharmacokinetic ascending dose Phase I Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive malignant in Advanced Malignant solid Tumors.

Clinical Study Identifier: NCT02881138

Find a site near you

Start Over